Savannah Biby

Savannah Biby

Auto-generated profile, based on publicly available information

Savannah Biby

Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YXYiming Xu
Yiming Xu
HBHallie Blevins
Hallie Blevins
SBSavannah Biby
Savannah Biby
JNJannatun N. Namme
Jannatun N. Namme
KZKun Zhang
Kun Zhang
SZShijun Zhang
Shijun Zhang
The NLRP3 inflammasome has recently emerged as a viable drug target, and small-molecule inhibitors of this protein complex are being actively tested in preclinical disease models. However, the mechanisms of action for the majority of these compounds remain unclear. Our recent medicinal chemistry campaign led to the discovery of several potent lead NLRP3 inhibitors from a distinct chemical scaffold. Herein, further characterization using biophysical, biochemical, chemical biology, and molecular biology approaches of one of the lead inhibitors revealed direct binding to the NACHT domain of the NLRP3 protein. The studies also suggested potentially multiple binding sites within the NACHT domain that can be targeted by different small-molecule inhibitors. Furthermore, an activity-based probe with high labeling efficacy was developed and can serve as a valuable tool to contribute to ongoing efforts in understanding NLRP3 biology and in developing NLRP3-targeted therapies for various diseases.

19 September 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
SBSavannah Biby
Savannah Biby
PMPrasenjit Mondal
Prasenjit Mondal
Yiming XuYiming Xu
Yiming Xu
AGAshley Gomm
Ashley Gomm
BKBaljit Kaur
Baljit Kaur
Can ZhangCan Zhang
Can Zhang
Considerable evidence indicates that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome plays key roles in human pathophysiology, suggesting it as a potential drug target. Currently, studies have yet to develop compounds that are promising therapeutics in the clinic by targeting the NLRP3 inflammasome. Herein, we aim to further biologically characterize a previously identified small-molecule inhibitor of the NLRP3 inflammasome from our group, YM-I-26, to confirm its functional activities. We showed that YM-I-26 is highly selective toward the NLRP3 inflammasome and binds to NLRP3 directly. A systemic analysis revealed YM-I-26 with inflammation-related and immunomodulatory activities by the Eurofins BioMAP Diversity PLUS panel. In addition, studies using the mouse microglia BV2 cell model demonstrated that YM-I-26 is not cytotoxic, improved the phagocytotic functions of BV2 cells toward beta-amyloid, and suppressed the production of cytokines of IL-1 beta and IL-10 upon the activation of the NLRP3 inflammasome. Collectively, our studies support the functional activities of YM-I-26 as a NLRP3 inhibitor in physiologically relevant cell models, and warrant future studies of YM-I-26 and its analogs to advance the drug development as potential therapeutics.

12 September 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YXYiming Xu
Yiming Xu
JNJannatun Namme
Jannatun Namme
LYLiuyue Yang
Liuyue Yang
YXYulong Xu
Yulong Xu
SBSavannah Biby
Savannah Biby
SZShijun Zhang
Shijun Zhang